Chemotherapy and immunotherapy combination for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with bile duct cancer (confirmed by biopsy or cytology) that cannot be surgically removed
- Never received chemotherapy or immunotherapy before (some prior surgery is okay)
- Good overall health and able to perform daily activities with minimal help (ECOG 0–1)
- At least one measurable tumor visible on imaging scans
- Blood counts, liver function, and kidney function meet safety thresholds for chemotherapy
- No current serious infections, autoimmune diseases, or recent heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a combination of drugs to treat advanced bile duct cancer that cannot be removed by surgery. The treatment may help shrink tumors and improve outcomes.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.